(Reuters) – Thermo Fisher Scientific said on Tuesday it would acquire Olink Holding AB in a deal valued at $3.1 billion as the U.S. medical equipment maker seeks to boost its life sciences portfolio that helps in drug discovery.
Thermo Fisher said it would pay the Sweden-based provider of protein analysis products $26.00 per common share in cash.
The deal, expected to be completed by mid-2024, represents a premium of about 74% to Olink’s closing price on Monday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Shilpi Majumdar)
